Literature DB >> 22908320

Vascular access type and risk of mortality in a national prospective cohort of haemodialysis patients.

B D Bray1, J Boyd, C Daly, K Donaldson, A Doyle, J G Fox, A Innes, I Khan, R K Peel, A Severn, I Shilliday, K Simpson, G A Stewart, J Traynor, W Metcalfe.   

Abstract

BACKGROUND: Central venous catheters (CVC) are a potential source of bacteraemia and have been associated with increased mortality in haemodialysis patients. We aimed to investigate the relationships between haemodialysis vascular access, taking into account changes in vascular access type during patients' lives, and cause specific mortality risk in a national cohort of dialysis patients.
METHODS: Prospective cohort study including all patients receiving haemodialysis in Scotland at annual cross sectional surveys in 2009, 2010 and 2011. Data were collected through the Scottish Renal Registry and by a structured review of case records following death. Cox proportional hazards regression and multivariable logistic regression were used to model survival and risk of death from septicaemia respectively.
RESULTS: Of a cohort of 2666 patients, 873 (32%) died during follow-up. After case-mix adjustment, patients using only tunnelled CVC during follow-up had a higher risk of all cause mortality across all strata of prior renal replacement therapy exposure [adjusted hazard ratio (HR): 1.83-2.08]. Case-mix adjusted risks of cardiovascular death (adjusted HR: 2.20-2.95) and infection-related death (adjusted HR: 3.10-3.63) were also higher in this group. Patients using tunnelled CVCs during follow-up and prior to death had 6.9-fold higher odds of death from septicaemia compared with those using only arteriovenous fistulae or grafts.
CONCLUSION: Compared with an arteriovenous fistula or graft, sustained use of tunnelled CVCs for vascular access is associated with higher risks of all-cause, cardiovascular and infection-related mortality.

Entities:  

Mesh:

Year:  2012        PMID: 22908320     DOI: 10.1093/qjmed/hcs143

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  9 in total

1.  Long-Term Functional Patency and Cost-Effectiveness of Arteriovenous Fistula Creation under Regional Anesthesia: a Randomized Controlled Trial.

Authors:  Emma Aitken; Rachel Kearns; Lucian Gaianu; Andrew Jackson; Mark Steven; John Kinsella; Marc Clancy; Alan Macfarlane
Journal:  J Am Soc Nephrol       Date:  2020-07-24       Impact factor: 10.121

2.  Effect of far infrared therapy on arteriovenous fistula maturation, survival and stenosis in hemodialysis patients, a randomized, controlled clinical trial: the FAITH on fistula trial.

Authors:  K Lindhard; M Rix; J G Heaf; H P Hansen; B L Pedersen; B L Jensen; D Hansen
Journal:  BMC Nephrol       Date:  2021-08-21       Impact factor: 2.388

Review 3.  Challenges and novel therapies for vascular access in haemodialysis.

Authors:  Jeffrey H Lawson; Laura E Niklason; Prabir Roy-Chaudhury
Journal:  Nat Rev Nephrol       Date:  2020-08-24       Impact factor: 28.314

4.  The characteristics and outcome of bacteraemia in renal transplant recipients and non-transplant renal patients.

Authors:  Mark Melzer; Territa Santhakumaran; Catherine Welch
Journal:  Infection       Date:  2016-05-02       Impact factor: 3.553

5.  Renal function, uraemia and early arteriovenous fistula failure.

Authors:  Emma Aitken; Andrew Jackson; Chia Kong; Paul Coats; David Kingsmore
Journal:  BMC Nephrol       Date:  2014-11-17       Impact factor: 2.388

6.  Immediate access arteriovenous grafts versus tunnelled central venous catheters: study protocol for a randomised controlled trial.

Authors:  Emma Aitken; Colin Geddes; Pete Thomson; Ram Kasthuri; Mohan Chandramohan; Colin Berry; David Kingsmore
Journal:  Trials       Date:  2015-02-08       Impact factor: 2.279

7.  The Type of Vascular Access and the Incidence of Mortality in Japanese Dialysis Patients.

Authors:  Toshikazu Ozeki; Hideaki Shimizu; Yoshiro Fujita; Daijo Inaguma; Shoichi Maruyama; Yukako Ohyama; Shun Minatoguchi; Yukari Murai; Maho Terashita; Tomoki Tagaya
Journal:  Intern Med       Date:  2017-03-01       Impact factor: 1.271

8.  Increased vulnerability to COVID-19 in chronic kidney disease.

Authors:  N Carlson; K-E Nelveg-Kristensen; E Freese Ballegaard; B Feldt-Rasmussen; M Hornum; A-Lise Kamper; G Gislason; C Torp-Pedersen
Journal:  J Intern Med       Date:  2021-02-10       Impact factor: 13.068

9.  Direct arterial puncture for hemodialysis, a neglected but simple and valuable vascular access.

Authors:  Chun-Yan Sun; Mi Zhong; Li Song; Ying-Gui Chen; Zi-Lin Quan; Li-Yan Zhao; Dong-Mei Cui; Xia Fu
Journal:  BMC Nephrol       Date:  2022-06-23       Impact factor: 2.585

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.